ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis - Slideshow

SignalsMonitor is following this as a markets story. Seeking Alpha is the outlet attached so far. The first report grouped here was at 24 Sept 2026, 17:10 UTC. 2 material updates are listed in the timeline. The headline in use is “ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease…”. This note is SignalsMonitor's own briefing, not the publisher's article.